Oura $2.2B IPO Is a Shareholder Payday as Forerunner Ventures Plans $1.26B Exit

TL;DR

• Oura's $2.2 billion IPO is overwhelmingly a secondary sale, meaning most of the proceeds will go to existing shareholders cashing out rather than to Oura for growth.
• Forerunner Ventures plans to sell its entire Oura stake in the offering for up to $1.26 billion, marking one of the largest consumer hardware VC exits in recent years.
• New investors get limited fresh capital upside and a premium valuation tied to subscriptions and AI health features, not just ring sales.

A $2.2 Billion IPO That Isn't Really For Oura

Oura is finally going public, but not in the way growth-stage investors might hope. The smart ring maker filed for an IPO targeting up to $2.2 billion in total offering value, and the paperwork makes one thing clear: this is largely a shareholder payday.

Instead of raising billions to fund factories, R&D, and expansion, Oura itself is selling only a small slice of new primary shares. The vast majority of the deal is made up of secondary shares — stock being sold by current backers and insiders. In other words, money from Wall Street won't flow into Oura's bank account. It will flow out to the venture firms that bet early on finger-worn health tracking.

For a profitable-on-an-adjusted-basis, subscription-driven wearables company, that structure is telling. It suggests Oura doesn't desperately need cash, but its long-time investors are ready for liquidity after nearly a decade of holding.

Forerunner's $1.26 Billion Full Exit

The headline seller is Forerunner Ventures. The early-stage consumer fund, which first backed Oura in 2015 when smart rings were still a curiosity, plans to sell its entire stake in the IPO for up to $1.26 billion.

That figure accounts for more than half of the total $2.2 billion offering size and instantly makes this one of Forerunner's biggest wins ever — on par with its exits in Warby Parker, Dollar Shave Club, and Glossier, but potentially larger in absolute dollars.

Selling 100% is unusual. Most top-tier VCs sell in tranches, keeping a position for post-IPO upside. A full exit signals three things: massive paper returns that need to be returned to limited partners, confidence that the IPO price represents a peak private-market valuation, and a portfolio shift away from hardware risk toward AI and software.

Forerunner is not alone. The filing lists other early backers including Lifeline Ventures, Temasek, and Fidelity-affiliated funds as selling shareholders, though none at Forerunner's scale. Founders and executives are largely holding on, which helps soften the optics of the sell-off.

What It Signals About Oura's Valuation

A $2.2 billion all-secondary-plus-primary float points to a fully diluted valuation well north of $10 billion. Oura last raised privately at around a $5.2 billion valuation in 2025, and reportedly topped $11 billion in secondary tender activity earlier this year.

Forerunner's ability to command up to $1.26 billion for its stake implies underwriters believe public market demand can support that markup — a bet that Oura is no longer valued as a gadget company, but as a health data platform.

The bull case rests on recurring revenue. Oura now counts more than 2.5 million active members paying $5.99 to $6.99 per month for Oura Membership, pushing annual recurring subscription revenue into the hundreds of millions on top of $500 million-plus in annual hardware sales. Gross margins above 65%, expanding use of AI coaching through Oura Advisor, and FDA-cleared sleep and heart health features are central to justifying a SaaS-like multiple.

The bear case is concentration. One product, one finger, heavy reliance on holiday cycles, and growing competition from Samsung Galaxy Ring, Apple, and Whoop.

What New Investors Need To Know

If you're thinking of buying at the IPO, understand what you're buying into: very little dilution for growth, a lot of insider selling, and a price set to let early investors exit whole.

Key risks from the filing to watch:

First, cash-in versus cash-out. Oura will net only a few hundred million from the primary portion, earmarked for working capital and R&D. It will not be flush with $2.2 billion.

Second, overhang and lockups. With Forerunner fully out, near-term overhang drops, which is positive. But remaining holders will still be subject to 180-day lockups, setting up a potential second wave of selling in early 2027.

Third, subscription dependence. Oura's S-1 frames future growth around retention, women's health, metabolic tracking, and enterprise partnerships with insurers and the Department of Defense. Any stall in paid conversion or churn uptick will hit the stock harder than hardware unit misses.

Fourth, profitability path. Oura touts adjusted profitability and strong unit economics, but remains unprofitable on a GAAP basis due to stock compensation and R&D. Public investors will demand a clear timeline to sustained net income.

The Bottom Line For Tech's Wearables Moment

Oura's IPO is a landmark for wearables and for consumer VC — proof that a $300 ring plus a monthly subscription can build a decacorn. But this $2.2 billion debut is engineered more for Forerunner and friends than for Oura's balance sheet.

That's not necessarily a red flag. Airbnb, Palantir, and Roblox all went public with heavy secondary components. It does mean new shareholders should price this as a mature, high-expectation health platform entering the public markets at a premium, not a discounted startup raising rocket fuel.

AndroGuider Team

Articles written by the AndroGuider team. We try to make them thorough and informational while being easy to read.